Relatlimab
Opdualag · Immune checkpoint inhibitor (anti-LAG-3)
2022 LAG-3 inhibitor (with nivolumab); class immune-mediated AIN, amplified by combination ICI.
Casodex · Bical
Nonsteroidal antiandrogen · approved 1995 · 4 citations · FAERS AKI reporting ROR 1.69 (95% CI 1.50–1.90, 271 AKI reports)
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
Nonsteroidal antiandrogen for prostate cancer; largely kidney-neutral with no renal dose adjustment and only rare interstitial nephritis reports.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Bicalutamide is largely kidney-neutral. Pharmacokinetics are unaffected by renal impairment and no renal dose adjustment is required. Acute interstitial nephritis is, at most, a rare idiosyncratic case-report-level event; no meaningful incidence rate is established.Source: Cockshott et al., Clin Pharmacokinet 2004 (no renal dose adjustment; AIN rare/idiosyncratic)
Idiosyncratic AIN, when it occurs, is typically subacute over weeks of exposure.
Distilled from: “If AIN occurs, typically subacute over weeks of exposure (idiosyncratic).”
This agent's defining kidney lesion — its #1 signature. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Immune-mediated inflammation of the renal interstitium — the signature kidney injury of checkpoint inhibitors.
Also documented as kidney-sparing
Bicalutamide — No direct renal injury. Hepatotoxicity (monitor LFTs).
The sparedBicalutamide is a nonsteroidal pure antiandrogen; its activity resides almost exclusively in the (R)-enantiomer, which competitively binds the androgen receptor and blocks androgen-driven transcription, inhibiting growth of androgen-dependent prostate cancer. It is used as monotherapy or combined with LHRH analogs/castration.
Interstitium
Supporting tissue around the tubules
Class-level context for the major non-renal toxicities of the Nonsteroidal antiandrogen class.
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
Musculoskeletal
Myalgia, myositis, rhabdomyolysis, ONJ
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
3 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (Apr 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
Renal impairment (as measured by creatinine clearance) had no significant effect on the elimination of total bicalutamide or the active R-enantiomer.
Kidney rows of the label's dosage tables
None of the newest openFDA labels for this product carries a dosage table. The label's prose can still give kidney instructions.
Everything below is FAERS — adverse events someone chose to report, about 15,311 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
2,754 of 15,311 reports
Reported with hospitalization
5,516 of 15,311 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 4,695 of the 15,311 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Bicalutamide sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Opdualag · Immune checkpoint inhibitor (anti-LAG-3)
2022 LAG-3 inhibitor (with nivolumab); class immune-mediated AIN, amplified by combination ICI.
Cotellic · MEK inhibitor
Real-world AKI signal with BRAF partners.
Braftovi · BRAF inhibitor
Class tubular signal; usually mild.
Zydelig · PI3Kδ inhibitor
Immune-mediated colitis → volume-depletion prerenal AKI; transaminitis.
Copiktra · PI3Kδ/γ inhibitor
Colitis and diarrhea → prerenal AKI.
Immune checkpoint inhibitor
Acute interstitial nephritis with long latency.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Bicalutamide’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Bicalutamide; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 9 clinical records among all 12 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.